OncoMatch/Clinical Trials/NCT06791083
Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Is NCT06791083 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Envafolimab and Fruquintinib for gastric cancer.
Treatment: Envafolimab · Fruquintinib — To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) positive
Known HER2-positive patients
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any systemic anti-tumor therapy
received other systemic anti-tumor therapy, including chemotherapy, signal transduction inhibitors, immunotherapy, and other investigational drugs within 4 weeks prior to enrollment
Cannot have received: investigational drug
Participated in other drug clinical trials and received at least one drug therapy within 4 weeks prior to enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min; endogenous creatinine clearance > 50ml/min
Liver function
Total bilirubin < 1.5 ULN; ALT and AST < 2.5 ULN (< 5 ULN in patients with liver metastasis)
Cardiac function
NYHA heart function Grade ≤ II and left ventricular ejection fraction (LVEF) ≥ 50%
Absolute neutrophil count ≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥90g/L; Total bilirubin < 1.5 ULN; ALT and AST < 2.5 ULN (< 5 ULN in patients with liver metastasis); Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min; endogenous creatinine clearance > 50ml/min; NYHA heart function Grade > II or left ventricular ejection fraction (LVEF) < 50% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify